Cargando…

Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis

BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory disease treated by nonsteroidal anti-inflammatory drugs (NSAIDs) including lornoxicam (LX). Nanocarriers have been used to increase the efficacy and reduce the side effects of various drugs. The objective of the present study was to com...

Descripción completa

Detalles Bibliográficos
Autores principales: Helmy, Hebatullah Samy, El-Sahar, Ayman E, Sayed, Rabab H, Shamma, Rehab Nabil, Salama, Alaa Hamed, Elbaz, Eman Maher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626385/
https://www.ncbi.nlm.nih.gov/pubmed/29026298
http://dx.doi.org/10.2147/IJN.S147738
_version_ 1783268535836868608
author Helmy, Hebatullah Samy
El-Sahar, Ayman E
Sayed, Rabab H
Shamma, Rehab Nabil
Salama, Alaa Hamed
Elbaz, Eman Maher
author_facet Helmy, Hebatullah Samy
El-Sahar, Ayman E
Sayed, Rabab H
Shamma, Rehab Nabil
Salama, Alaa Hamed
Elbaz, Eman Maher
author_sort Helmy, Hebatullah Samy
collection PubMed
description BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory disease treated by nonsteroidal anti-inflammatory drugs (NSAIDs) including lornoxicam (LX). Nanocarriers have been used to increase the efficacy and reduce the side effects of various drugs. The objective of the present study was to compare the therapeutic efficacy of systemic administration of lornoxicam-loaded nanomicellar formula (LX-NM) with that of free LX. MATERIALS AND METHODS: The LX-loaded mixed polymeric nanomicellar formula was prepared by direct equilibrium technique. Two rat models were used in the study: carrageenan-induced acute edema and Freund’s complete adjuvant (FCA)-induced chronic arthritis. RESULTS: The inhibitory effect of LX-NM on carrageenan-induced edema was higher than free LX for the same dose (1.3 mg/kg, i.p.). LX-NM (0.325 mg/kg, i.p.) produced effects comparable to that of diclofenac, which served as a standard. In the FCA model, daily treatment with LX-NM (0.325 mg/kg, i.p.) starting on day 14 significantly reduced the percentage of edema and increased weight growth. However, the same dose of LX failed to confer any significant change. Additionally, LX-NM significantly attenuated the rise of tumor necrosis factor-α (TNF-α), interleukin-1β, prostaglandin E2, nuclear factor-κβ, malondialdehyde and nitric oxide serum levels. In contrast, LX failed to show any significant reduction in elevated serum biomarkers except for TNF-α. CONCLUSION: LX-NM is an alternative delivery system that is simply prepared at low costs. It showed a superior therapeutic efficacy against RA compared to free LX. Thus, LX-NM can be considered as a promising candidate for treatment of RA and similar inflammatory disorders.
format Online
Article
Text
id pubmed-5626385
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56263852017-10-12 Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis Helmy, Hebatullah Samy El-Sahar, Ayman E Sayed, Rabab H Shamma, Rehab Nabil Salama, Alaa Hamed Elbaz, Eman Maher Int J Nanomedicine Original Research BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory disease treated by nonsteroidal anti-inflammatory drugs (NSAIDs) including lornoxicam (LX). Nanocarriers have been used to increase the efficacy and reduce the side effects of various drugs. The objective of the present study was to compare the therapeutic efficacy of systemic administration of lornoxicam-loaded nanomicellar formula (LX-NM) with that of free LX. MATERIALS AND METHODS: The LX-loaded mixed polymeric nanomicellar formula was prepared by direct equilibrium technique. Two rat models were used in the study: carrageenan-induced acute edema and Freund’s complete adjuvant (FCA)-induced chronic arthritis. RESULTS: The inhibitory effect of LX-NM on carrageenan-induced edema was higher than free LX for the same dose (1.3 mg/kg, i.p.). LX-NM (0.325 mg/kg, i.p.) produced effects comparable to that of diclofenac, which served as a standard. In the FCA model, daily treatment with LX-NM (0.325 mg/kg, i.p.) starting on day 14 significantly reduced the percentage of edema and increased weight growth. However, the same dose of LX failed to confer any significant change. Additionally, LX-NM significantly attenuated the rise of tumor necrosis factor-α (TNF-α), interleukin-1β, prostaglandin E2, nuclear factor-κβ, malondialdehyde and nitric oxide serum levels. In contrast, LX failed to show any significant reduction in elevated serum biomarkers except for TNF-α. CONCLUSION: LX-NM is an alternative delivery system that is simply prepared at low costs. It showed a superior therapeutic efficacy against RA compared to free LX. Thus, LX-NM can be considered as a promising candidate for treatment of RA and similar inflammatory disorders. Dove Medical Press 2017-09-22 /pmc/articles/PMC5626385/ /pubmed/29026298 http://dx.doi.org/10.2147/IJN.S147738 Text en © 2017 Helmy et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Helmy, Hebatullah Samy
El-Sahar, Ayman E
Sayed, Rabab H
Shamma, Rehab Nabil
Salama, Alaa Hamed
Elbaz, Eman Maher
Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis
title Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis
title_full Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis
title_fullStr Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis
title_full_unstemmed Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis
title_short Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis
title_sort therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626385/
https://www.ncbi.nlm.nih.gov/pubmed/29026298
http://dx.doi.org/10.2147/IJN.S147738
work_keys_str_mv AT helmyhebatullahsamy therapeuticeffectsoflornoxicamloadednanomicellarformulainexperimentalmodelsofrheumatoidarthritis
AT elsaharaymane therapeuticeffectsoflornoxicamloadednanomicellarformulainexperimentalmodelsofrheumatoidarthritis
AT sayedrababh therapeuticeffectsoflornoxicamloadednanomicellarformulainexperimentalmodelsofrheumatoidarthritis
AT shammarehabnabil therapeuticeffectsoflornoxicamloadednanomicellarformulainexperimentalmodelsofrheumatoidarthritis
AT salamaalaahamed therapeuticeffectsoflornoxicamloadednanomicellarformulainexperimentalmodelsofrheumatoidarthritis
AT elbazemanmaher therapeuticeffectsoflornoxicamloadednanomicellarformulainexperimentalmodelsofrheumatoidarthritis